Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
12 2021
Historique:
received: 07 02 2021
accepted: 06 07 2021
revised: 06 07 2021
pubmed: 28 7 2021
medline: 19 3 2022
entrez: 27 7 2021
Statut: ppublish

Résumé

Undifferentiated mesenchymal tumors arising from the inner lining (intima) of large arteries are classified as intimal sarcomas (ISA) with MDM2 amplification as their molecular hallmark. Interestingly, undifferentiated pleomorphic sarcomas (UPS) of the heart have recently been suggested to represent the cardiac analog of ISA due to morphological overlap and high prevalence of MDM2 amplifications in both neoplasms. However, little is known about ISAs and cardiac UPS without MDM2 amplifications and molecular data supporting their common classification is sparse. Here, we report a series of 35 cases comprising 25 ISAs of the pulmonary artery, one ISA of the renal artery and 9 UPS of the left atrium. Tumors were analyzed utilizing the Illumina Infinium MethylationEPIC BeadChip array, enabling copy number profile generation and unsupervised DNA methylation analysis. DNA methylation patterns were investigated using t-distributed stochastic neighbor embedding (t-SNE) analysis. Histologically, all ISAs and UPS of the left atrium resembled extra-cardiac UPS. All cases exhibited highly complex karyotypes with overlapping patterns between ISA and UPS. 29/35 cases showed mutually exclusive amplifications in the cell-cycle associated oncogenes MDM2 (25/35), MDM4 (2/35), and CDK6 (2/35). We further observed recurrent co-amplifications in PDGFRA (21/35), CDK4 (15/35), TERT (11/35), HDAC9 (9/35), and CCND1 (4/35). Sporadic co-amplifications occurred in MYC, MYCN, and MET (each 1/35). The tumor suppressor CDKN2A/B was frequently deleted (10/35). Interestingly, DNA methylation profiling (t-SNE) revealed an overlap of ISA and cardiac UPS. This "ISA" methylation signature was distinct from potential histologic and molecular mimics. In conclusion, our data reveal MDM4 and CDK6 amplifications in ISAs and UPS of the left atrium, lacking MDM2 amplification. We further report novel co-amplifications of various oncogenes, which may have therapeutic implications. Finally, the genetic and epigenetic concordance of ISAs and UPS of the left atrium further supports a shared pathogenesis and common classification.

Identifiants

pubmed: 34312479
doi: 10.1038/s41379-021-00874-y
pii: S0893-3952(22)00372-6
pmc: PMC8592836
mid: NIHMS1757509
doi:

Substances chimiques

Biomarkers, Tumor 0
Cell Cycle Proteins 0
DNA, Neoplasm 0
MDM4 protein, human 0
Neoplasm Proteins 0
Proto-Oncogene Proteins 0
MDM2 protein, human EC 2.3.2.27
Proto-Oncogene Proteins c-mdm2 EC 2.3.2.27
CDK6 protein, human EC 2.7.11.22
Cyclin-Dependent Kinase 6 EC 2.7.11.22

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2122-2129

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Acta Neuropathol. 2018 Aug;136(2):181-210
pubmed: 29967940
Clin Cancer Res. 2020 Jan 1;26(1):93-100
pubmed: 31562204
Acta Neuropathol. 2016 Jun;131(6):877-87
pubmed: 26857854
Acta Neuropathol. 2018 Aug;136(2):327-337
pubmed: 29881993
Acta Neuropathol. 2013 Jun;125(6):913-6
pubmed: 23670100
Virchows Arch. 2017 Sep;471(3):423-428
pubmed: 28474091
Cancer Cell. 2015 May 11;27(5):728-43
pubmed: 25965575
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Am J Surg Pathol. 2008 Dec;32(12):1751-61
pubmed: 18779732
Cancer. 2020 Jan 1;126(1):98-104
pubmed: 31536651
Oncol Res Treat. 2017;40(6):353-359
pubmed: 28501860
BMJ Case Rep. 2018 Sep 30;2018:
pubmed: 30275026
Clin Cancer Res. 2010 Jun 15;16(12):3240-52
pubmed: 20413433
J Pathol. 2004 Jul;203(3):822-30
pubmed: 15221942
Am J Surg Pathol. 2014 Mar;38(3):293-304
pubmed: 24525499
Nat Rev Cancer. 2011 Jul 14;11(8):541-57
pubmed: 21753790
Cancer Res. 2010 Sep 15;70(18):7304-14
pubmed: 20685895
Virchows Arch. 2001 Jan;438(1):57-65
pubmed: 11213836
Pathology. 2014 Dec;46(7):596-603
pubmed: 25393249
J Thorac Oncol. 2016 Apr;11(4):441-52
pubmed: 26725181
Nat Commun. 2021 Jan 21;12(1):498
pubmed: 33479225
Int J Cancer. 2020 Dec 1;147(11):2988-2995
pubmed: 32406095
Clin Sarcoma Res. 2019 Feb 14;9:2
pubmed: 30809375
Cancer Genet Cytogenet. 2007 Dec;179(2):146-9
pubmed: 18036403
J Mol Cell Biol. 2019 Mar 1;11(3):231-244
pubmed: 30689920
Cell. 2017 Nov 2;171(4):950-965.e28
pubmed: 29100075
Am J Surg Pathol. 2014 Aug;38(8):1158-9
pubmed: 24921645
Cancers (Basel). 2019 Aug 31;11(9):
pubmed: 31480474
Mod Pathol. 2018 Aug;31(8):1246-1256
pubmed: 29572501
Genes Chromosomes Cancer. 2002 May;34(1):48-57
pubmed: 11921282
Ann Diagn Pathol. 2020 Feb;44:151434
pubmed: 31887709
Mod Pathol. 2003 Mar;16(3):256-62
pubmed: 12640106
J Cancer Res Clin Oncol. 2020 Jan;146(1):97-104
pubmed: 31768620
Nat Genet. 2010 Aug;42(8):715-21
pubmed: 20601955
Cancer. 1993 Mar 1;71(5):1761-73
pubmed: 8448740
Am J Surg Pathol. 2005 Sep;29(9):1184-93
pubmed: 16096408
Virchows Arch. 1999 Nov;435(5):473-8
pubmed: 10592050
Oncogene. 2019 Aug;38(34):6172-6183
pubmed: 31285550
Am J Surg Pathol. 2014 Oct;38(10):1449
pubmed: 25216322
J Pathol. 2020 Dec;252(4):433-440
pubmed: 32866294
Am J Surg Pathol. 2014 Apr;38(4):461-9
pubmed: 24625414
Mod Pathol. 2020 Mar;33(3):456-467
pubmed: 31383964

Auteurs

Christian Koelsche (C)

Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. Christian.Koelsche@med.uni-heidelberg.de.

Jamal K Benhamida (JK)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.

Felix K F Kommoss (FKF)

Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Damian Stichel (D)

Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

David T W Jones (DTW)

Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Paediatric Glioma Research Group, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Stefan M Pfister (SM)

Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.

Christoph E Heilig (CE)

Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.

Stefan Fröhling (S)

Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.

Albrecht Stenzinger (A)

Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Rolf Buslei (R)

Institute of Pathology, Sozialstiftung Bamberg, Bamberg, Germany.

Thomas Mentzel (T)

Dermatopathology Bodensee, Friedrichshafen, Germany.

Daniel Baumhoer (D)

Bone Tumor Reference Center at the Institute of Medical Genetics and Pathology, University Hospital and University of Basel, Basel, Switzerland.

Marc Ladanyi (M)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.

Cristina R Antonescu (CR)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.

Uta Flucke (U)

Department of Pathology, Radboud University Hospital, Nijmegen, the Netherlands.

Joost van Gorp (JV)

Department of Pathology, St Antonius Hospital Nieuwegein, Nieuwegein, the Netherlands.

Beata Bode-Lesniewska (B)

Department of Pathology, University Hospital, Zurich, Switzerland.

Andreas von Deimling (AV)

Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Gunhild Mechtersheimer (G)

Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH